Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > StageZero Life Sciences Announces Availability of COC Protoc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(445)
•••
Comment by Liked2Thinkon Mar 14, 2022 3:00pm
66 Views
Post# 34512656

RE:RE:StageZero Life Sciences Announces Availability of COC Protoc

RE:RE:StageZero Life Sciences Announces Availability of COC Protochahaha

Oh the latest fluff piece.

Why not use the new exciting opportunities in Europe approach as they did before.

Do you think Oncore will be a part of it? HA!

Oncore is too busy with that $60M contract with iBodyCheck! HAHAH

I guess if you wait long enough after one scam you can change some words and use it as a new scam.

COC is available in Europe sounds alot like "Aristotle is available Apr 1" BS. Maybe in a year they might do one test in Europe.

News flash.  This is just another BS NR so they can try and bump this pig up to 20 cents a share so that is where they can do the next PP that should be released in 2 weeks or so.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities